This article is more than 5 years old. Information may no longer be current.

Opko Health completes enrollment for phase 3 trial of compound for AMD treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MIAMI — Opko Health has completed enrollment for a phase 3 safety and efficacy trial of bevasiranib for treating wet age-related macular degeneration, the company announced in a press release.

Bevasiranib is a small interfering RNA compound designed to deactivate the genes that produce vascular endothelial growth factor. Bevasiranib is the first drug based on the concept of RNA interference (RNAi) to advance to phase 3 clinical trials, according to the release.

The study has enrolled more than 330 patients and will evaluate the vision loss prevention of bevasiranib when administered in 8- and 12-week intervals.

"This first-ever phase 3 trial of an agent based on RNAi technology is a milestone in the field of RNAi," Phillip Frost, MD, chairman and chief executive officer of Opko Health, said in the release. "With the completion of enrollment, we are one step closer to our goal of submitting a new drug application to regulatory agencies worldwide."